Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Filter Content:
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Video & Webinars
Oncology
26 Jun 2015
Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…
Oncology
26 Jun 2015
DNMT3A R882 mutations in AML promote chemoresistance and therapeutic relapse
Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882…
Oncology
26 Jun 2015
Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML
The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free…
Hematology
26 Jun 2015
The crucial roles of GFI1B in platelet development
The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result in the…
Hematology
26 Jun 2015
Pacritinib therapy led to symptom improvement in myelofibrosis
The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more…
Hematology
26 Jun 2015
Treatment and outcome of CML patients from the EUTOS population-based registry
The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML).
Hematology
26 Jun 2015
Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL
n a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination…
Hematology
26 Jun 2015
Adding elotuzumab to standard treatment for myeloma reduced disease progression
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory…
Loading posts...
« Previous
1
…
98
99
100
101
102
…
109
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View
